What are the advantages of brexpiprazole compared with aripiprazole?

Brexpiprazole vs Aripiprazole: Key Advantages

Brexpiprazole offers a significantly lower risk of akathisia and extrapyramidal side effects compared to aripiprazole, while maintaining comparable antipsychotic efficacy. This makes it a superior choice when movement-related side effects are a concern, particularly in patients who have previously experienced akathisia on aripiprazole.

Primary Advantages of Brexpiprazole

Lower Akathisia Risk

The most clinically significant advantage is the reduced incidence of akathisia. In a direct comparison study, brexpiprazole caused akathisia in only 9.4% of patients versus 21.2% with aripiprazole 1. This stems from brexpiprazole's lower intrinsic activity at D2 receptors—it has less D2 receptor activation relative to blockade compared to aripiprazole 2, 3.

Enhanced Receptor Profile

Brexpiprazole demonstrates:

• More potent 5-HT1A receptor activity than aripiprazole 4, 5
• Lower intrinsic D2 receptor activity (less "partial agonism") 4
• Stronger antihistaminic activity, which translates to better sedation, lower akathisia risk, and reduced agitation/insomnia 2

This unique pharmacological profile produces robust antipsychotic effects with limited extrapyramidal symptom liability 4.

Comparable Efficacy with Better Tolerability

Both drugs demonstrate equivalent antipsychotic efficacy in reducing positive symptoms of schizophrenia 1. In the direct comparison study, PANSS total score reductions were -22.9 for brexpiprazole versus -19.4 for aripiprazole 1. However, brexpiprazole achieved this with superior tolerability.

Additional Clinical Benefits

• Reduction in impulsivity: Brexpiprazole showed modest reductions in impulsivity (BIS-11 score change: -2.7) while aripiprazole showed none (0.1) 1
• Negative symptom improvement: Effective for residual negative symptoms, particularly when combined with other antipsychotics 6, 7
• Functional outcomes: Positive effects on social functioning, personal functioning, and quality of life beyond symptom reduction 2
• Depressive and anxiety symptoms: Demonstrated efficacy in reducing both depressive symptoms and anxiety in schizophrenia patients 2

Weight and Metabolic Profile

Both drugs are relatively weight-neutral compared to other antipsychotics. Guidelines classify both aripiprazole and brexpiprazole as having lower risk for weight gain compared to olanzapine, clozapine, quetiapine, and risperidone 8, 9. When weight management is a priority in patients with obesity, switching to aripiprazole is recommended 9, and by extension, brexpiprazole would be equally appropriate given its similar metabolic profile.

Mortality and Safety

In real-world evidence from Medicare claims data involving 41,871 beneficiaries with dementia, brexpiprazole showed statistically lower 6-month mortality compared to aripiprazole (OR 0.49,95% CI 0.37-0.65) 10. There were no differences in emergency department visits or hospitalizations between the two drugs 10.

Dosing Considerations

Maximum effective doses differ significantly:

• Brexpiprazole: 1.6 mg for treatment-resistant depression 11; 4 mg for schizophrenia 12
• Aripiprazole: 5.5 mg for treatment-resistant depression 11; typically 15 mg for schizophrenia

For treatment-resistant depression, aripiprazole at 5.5-12.5 mg may be more effective than lower doses of brexpiprazole, though brexpiprazole 1-3 mg remains significantly superior to placebo 11.

Clinical Decision Algorithm

Choose brexpiprazole over aripiprazole when:

1. Patient has history of akathisia or extrapyramidal symptoms on aripiprazole
2. Patient requires sedation or has prominent insomnia/agitation
3. Impulsivity is a treatment target
4. Patient is elderly with dementia (lower mortality signal)

Choose aripiprazole over brexpiprazole when:

1. Higher doses needed for treatment-resistant depression (>5 mg equivalent)
2. Cost is a primary concern (aripiprazole is generic)
3. Activating properties are desired over sedation

Important Caveats

Both drugs share the same black box warnings for elderly patients with dementia-related psychosis (increased mortality risk) 12. However, the real-world evidence suggests brexpiprazole may actually have lower mortality than aripiprazole in this population 10.

Drug interactions are similar for both medications—both require dose adjustments with strong CYP3A4 and CYP2D6 inhibitors/inducers 12.

The primary trade-off is akathisia risk versus cost: brexpiprazole offers meaningfully lower movement disorder risk but at higher medication cost compared to generic aripiprazole.